Literature DB >> 26139628

Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model.

Misaki Nakajima1, Shotaro Nagase1, Manami Iida1, Shuji Takeda1, Mayo Yamashita1, Akihiro Watari1, Yoshitaka Shirasago1, Masayoshi Fukasawa1, Hiroyuki Takeda1, Tatsuya Sawasaki1, Kiyohito Yagi1, Masuo Kondoh2.   

Abstract

Tight junctions (TJs) are complex biochemical structures that seal the intercellular space and prevent the free movement of solutes across epithelial cell sheets. Modulating the TJ seal is a promising option for increasing the transdermal absorption of drugs. Within TJs, the binding of the claudin (CLDN) family of tetratransmembrane proteins through cis- and trans-interactions is an integral part of seal formation. Because epidermal TJs contain CLDN-1 and CLDN-4, a binder for these CLDNs may be a useful modulator of the permeability of the epidermal barrier. Here, we investigated whether m19, which can bind to CLDN-1/-4 (also CLDN-2/-5), modulates the integrity of epidermal TJs and the permeability of cell sheets to solutes. Treatment of normal human epidermal keratinocytes (NHEKs) with the CLDN binder reduced the integrity of TJs. A CLDN-1-specific binder (a monoclonal antibody, clone 7A5) also weakened the TJ seal in NHEKs. Although m19 attenuated the TJ barrier in human intestinal epithelial cells (Caco-2), 7A5 did not. Treatment of NHEKs with 7A5 enhanced permeation of a paracellular permeation marker. These findings indicate that CLDN-1 is a potential target for modulating the permeability of the epidermis, and that our CLDN-1 binder is a promising candidate molecule for development as a dermal absorption enhancer.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26139628     DOI: 10.1124/jpet.115.225391

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Tight junctions in skin inflammation.

Authors:  Katja Bäsler; Johanna M Brandner
Journal:  Pflugers Arch       Date:  2016-11-16       Impact factor: 3.657

2.  Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.

Authors:  Yoshimi Shimizu; Yoshitaka Shirasago; Masuo Kondoh; Tetsuro Suzuki; Takaji Wakita; Kentaro Hanada; Kiyohito Yagi; Masayoshi Fukasawa
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

3.  Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs.

Authors:  Lizandra Jimenez; Hui Yu; Andrew J McKenzie; Jeffrey L Franklin; James G Patton; Qi Liu; Alissa M Weaver
Journal:  J Proteome Res       Date:  2019-01-23       Impact factor: 4.466

Review 4.  Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes.

Authors:  Maliheh Ghadiri; Paul M Young; Daniela Traini
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

Review 5.  Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1.

Authors:  Yosuke Hashimoto; Keisuke Tachibana; Susanne M Krug; Jun Kunisawa; Michael Fromm; Masuo Kondoh
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

6.  Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells.

Authors:  Laura-Sophie Beier; Jan Rossa; Stephen Woodhouse; Sophia Bergmann; Holger B Kramer; Jonas Protze; Miriam Eichner; Anna Piontek; Sabine Vidal-Y-Sy; Johanna M Brandner; Gerd Krause; Nicole Zitzmann; Jörg Piontek
Journal:  Int J Mol Sci       Date:  2019-09-26       Impact factor: 5.923

7.  Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay.

Authors:  Akihiro Watari; Miki Kodaka; Koji Matsuhisa; Yuta Sakamoto; Kota Hisaie; Norihito Kawashita; Tatsuya Takagi; Yoshiaki Yamagishi; Hidehiko Suzuki; Hirofumi Tsujino; Kiyohito Yagi; Masuo Kondoh
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.